Cumberland Pharmaceuticals Inc.

CPIX · Nasdaq · United States

Share price · CPIX

$6.57-1.06 (-13.89%) 3M

close as of 2026-11-18 · 24h delayed · vol 163K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CPIX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026+12.8%

    Nothing announced by CPIX that day or the session before.

  2. 26 Oct 2026-48.8%
  3. 20 Oct 2026+18.8%
  4. 31 Aug 2026-20.9%
  5. 2 Jul 2026-10.7%
  6. 26 Jun 2026+13.3%
  7. 15 May 2026+11.2%
  8. 23 Apr 2026+27.9%
  9. 4 Mar 2026-19.9%
  10. 6 Jan 2026+18.0%

Share of unusual movement by asset

For each asset, the share of CPIX's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ifetroban
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—24%
Other company news (earnings, financing, releases naming no asset)—26%
Sessions with no dated event—50%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Thromboxane A2 receptor (TP receptor)
Systemic Sclerosis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
IfetrobanPhase 2Idiopathic Pulmonary Fibrosis
Est. primary completion 2028-01 · NCT05571059 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026Topline resultIfetrobanPhase 2 ASSIST-SSc pilot of ifetroban reports top-line safety results

Financial reports

Quarterly & interim (21)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$0.8M$81M—-$1.5M operating cash flowreport ↗
View 20 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$8.8M$0.8M$3.9M$4.3M$0.2M operating cash flowreport ↗
2026-Q1$9.1M$1.5M$11M$3.3M$0.4M operating cash flowreport ↗
2025-Q4$14M—$11M$1.4M$0 operating cash flowreport ↗
2025-Q3$8.3M$1.3M$15M$1.9M$0.2M operating cash flowreport ↗
2025-Q2$11M$1.5M$16M$0.7M$0.8M operating cash flowreport ↗
2025-Q1$12M$1.3M$15M—$3.9M operating cash flowreport ↗
2024-Q4$10M—$18M$1.9M$1.9M operating cash flowreport ↗
2024-Q3$9.1M$1.3M$17M$1.5M$0.5M operating cash flowreport ↗
2024-Q2$9.8M$1.1M$17M$1.1M-$0.9M operating cash flowreport ↗
2024-Q1$8.5M$1.2M$19M$1.9M-$2.1M operating cash flowreport ↗
2023-Q4$9.3M—$18M$6.3M$1.0M operating cash flowreport ↗
2023-Q3$10M$1.9M$19M$1.1M$1.2M operating cash flowreport ↗
2023-Q2$11M$1.1M$18M—$5.2M operating cash flowreport ↗
2023-Q1$9.2M$1.5M$16M—-$1.4M operating cash flowreport ↗
2022-Q4$9.1M—$20M$2.4M$3.6M operating cash flowreport ↗
2022-Q3$11M$1.7M$20M$0.4M$2.6M operating cash flowreport ↗
2022-Q2$10M$1.8M$18M$1.3M$2.3M operating cash flowreport ↗
2022-Q1$11M$1.8M$17M$1.4M-$0.1M operating cash flowreport ↗
2021-Q4——$27M$3.9M$2.0M operating cash flowreport ↗
2021-Q3$8.1M$1.4M$26M$1.1M-$0.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$45M$5.6M$11M$0.7M$4.9M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$38M$4.8M$18M$1.6M-$0.6M operating cash flowreport ↗
2023-FY$40M$5.8M$18M$1.6M$6.1M operating cash flowreport ↗
2022-FY$41M$6.7M$20M$1.4M$8.4M operating cash flowreport ↗
2021-FY$35M$5.7M$27M$0.9M$6.3M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-03-18KAZIMI A J · director, Chairman and CEO, 10% ownerAward / grant (derivative)100,000$2.80$280KForm 4
2026-03-18Herman James L · VP and Chief Compliance OfficeAward / grant (derivative)2,500$2.80$7KForm 4
2026-03-18Hamm John M. · VP Chief Financial OfficerAward / grant (derivative)3,000$2.80$8KForm 4
2026-03-18Bitterman Chris T. · Vice Pres Sales & MarketingAward / grant (derivative)3,000$2.80$8KForm 4
2026-03-18Anthony Todd M. · Vice Pres Organizational DevAward / grant (derivative)3,000$2.80$8KForm 4
2026-03-18Young Caroline · directorAward / grant1,800$2.80$5KForm 4
2026-03-18Krogulski Kenneth · directorAward / grant1,800$2.80$5KForm 4
2026-03-18Jones James · directorAward / grant1,800$2.80$5KForm 4